Design and in vitro Evaluation of Fluvoxamine Nanosuspension using PVA as Stabilizing Agent

IF 0.4 Q4 PHARMACOLOGY & PHARMACY Asian Journal of Pharmaceutics Pub Date : 2021-07-22 DOI:10.22377/ajp.v15i2.4061
M. Srinivas
{"title":"Design and in vitro Evaluation of Fluvoxamine Nanosuspension using PVA as Stabilizing Agent","authors":"M. Srinivas","doi":"10.22377/ajp.v15i2.4061","DOIUrl":null,"url":null,"abstract":"Introduction: Poor aqueous solubility and low dissolution rates are the initial drawback for the majority of upcoming and existing biologically active compounds. Materials and Methods: Fluvoxamine (API), other excipients such as PVA, SLS, Tween 80, and methanol. Fluvoxamine is a poorly water-soluble drug and its bioavailability is very low. The present study was to increase the solubility and dissolution rate of Fluvoxamine by formulating nanosuspensions by Emulsification solvent evaporation method. Results and Discussions: The formulation nanosuspenison was subject to zeta potential, particle size analysis, drug content, and in vitro drug release studies. The entrapment efficiency of all the formulations was within 95.78–98.16%, from the drug release studies, The NF6 formulation was optimized and it shows maximum drug release (99.02%) at a shorter period of time than remaining formulations. The average particle size of the optimized formulation was found to be 110 nm. Conclusion: The research showed that enhanced dissolution rate by reduced in particle size, which, in turn, increases the dissolution rate and oral bioavailability of fluvoxamine by formulating nanosuspensions. Formulations were found to physically stable with PVA as the stabilizing agent.","PeriodicalId":8489,"journal":{"name":"Asian Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2021-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22377/ajp.v15i2.4061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: Poor aqueous solubility and low dissolution rates are the initial drawback for the majority of upcoming and existing biologically active compounds. Materials and Methods: Fluvoxamine (API), other excipients such as PVA, SLS, Tween 80, and methanol. Fluvoxamine is a poorly water-soluble drug and its bioavailability is very low. The present study was to increase the solubility and dissolution rate of Fluvoxamine by formulating nanosuspensions by Emulsification solvent evaporation method. Results and Discussions: The formulation nanosuspenison was subject to zeta potential, particle size analysis, drug content, and in vitro drug release studies. The entrapment efficiency of all the formulations was within 95.78–98.16%, from the drug release studies, The NF6 formulation was optimized and it shows maximum drug release (99.02%) at a shorter period of time than remaining formulations. The average particle size of the optimized formulation was found to be 110 nm. Conclusion: The research showed that enhanced dissolution rate by reduced in particle size, which, in turn, increases the dissolution rate and oral bioavailability of fluvoxamine by formulating nanosuspensions. Formulations were found to physically stable with PVA as the stabilizing agent.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
聚乙烯醇为稳定剂的氟伏沙明纳米混悬液的设计与体外评价
水溶性差和溶解速率低是大多数即将到来和现有的生物活性化合物的最初缺点。材料和方法:氟伏沙明(API)、其他辅料如PVA、SLS、Tween 80、甲醇。氟伏沙明是一种水溶性差的药物,生物利用度很低。本研究采用乳化溶剂蒸发法制备氟伏沙明纳米混悬液,以提高其溶解度和溶出率。结果与讨论:通过zeta电位、粒度分析、药物含量和体外释药研究,确定了该纳米混悬剂的处方。各制剂的包封效率均在95.78 ~ 98.16%之间,从释药研究上看,优化后的NF6制剂在较短的时间内释药最大,释药率为99.02%。优化后的配方平均粒径为110 nm。结论:减小氟伏沙明纳米混悬液粒径可提高其溶出度,从而提高其口服生物利用度。以PVA为稳定剂的配方在物理上是稳定的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Asian Journal of  Pharmaceutics
Asian Journal of Pharmaceutics PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
47
期刊介绍: Character of the publications: -Pharmaceutics and Pharmaceutical Technology -Formulation Design and Development -Drug Discovery and Development Interface -Manufacturing Science and Engineering -Pharmacokinetics, Pharmacodynamics, and Drug Metabolism -Clinical Pharmacology, General Medicine and Translational Research -Physical Pharmacy and Biopharmaceutics -Novel Drug delivery system -Biotechnology & Microbiological evaluations -Regulatory Sciences
期刊最新文献
A Design of Experiment-based Approach for the Formulation Development and Evaluation of Repaglinide Transdermal Patch Using Natural Polymers Modification of Human Behavior due to Coronavirus Outbreak: A Brief Study on Current Scenario Formulation and Evaluation of Sustained Release Bilayer Tablets of Losartan Potassium Bioanalytical Method Development and Validation of Empagliflozin by LC–MS/MS Method and Quantitative Estimation of Drug Concentration in Human Plasma Formulation and Evaluation of Antidiabetic Polyherbal Tablets
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1